Cargando…

Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area

PURPOSE: Disproportionality screening analysis is acknowledged as a tool for performing signal detection in databases of adverse drug reactions (ADRs), e.g., in the European Union (EU) Drug Authority setting. The purpose of this study was to explore the possibility of decreasing false-positive signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Grundmark, Birgitta, Holmberg, Lars, Garmo, Hans, Zethelius, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978377/
https://www.ncbi.nlm.nih.gov/pubmed/24599513
http://dx.doi.org/10.1007/s00228-014-1658-1
_version_ 1782310556219211776
author Grundmark, Birgitta
Holmberg, Lars
Garmo, Hans
Zethelius, Björn
author_facet Grundmark, Birgitta
Holmberg, Lars
Garmo, Hans
Zethelius, Björn
author_sort Grundmark, Birgitta
collection PubMed
description PURPOSE: Disproportionality screening analysis is acknowledged as a tool for performing signal detection in databases of adverse drug reactions (ADRs), e.g., in the European Union (EU) Drug Authority setting. The purpose of this study was to explore the possibility of decreasing false-positive signals of disproportionate reporting (SDR) by calculating the proportional reporting ratio (PRR)-by-therapeutic area (TA), while still maintaining the ability to detect relevant SDRs. METHODS: In the EudraVigilance (EV) Database, output from PRR calculated with a restricted TA comparator background was compared in detail to output from conventional authority-setting PRR calculations for four drugs: bicalutamide, abiraterone, metformin, and vildagliptin, within the TAs of prostate gland disease and type 2 diabetes mellitus. RESULTS: ADR reports per investigated drug ranged from 2,400 to 50,000. The PRR-TA’s ability to detect true-positive SDRs (as acknowledged in approved labeling) was increased compared to the conventional PRR, and performed 8–31 % better than a recently proposed stricter EU-SDR definition. The PRR-TA removed false SDRs confounded by disease or disease spill-over by up to 63 %, while retaining/increasing the number of unclassified SDRs relevant for manual validation, and thereby improving the ratio between confounded SDRs (i.e., noise) and unclassified SDRs for all investigated drugs (possible signals). CONCLUSIONS: The performance of the PRR was improved by background restriction with the PRR-TA method; the number of false-positive SDRs decreased, and the ability to detect true-positive SDRs increased, improving the signal-to-noise ratio. Further development and validation of the method is needed within other TAs and databases, and for disproportionality analysis methods. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-014-1658-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3978377
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-39783772014-04-22 Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area Grundmark, Birgitta Holmberg, Lars Garmo, Hans Zethelius, Björn Eur J Clin Pharmacol Pharmacoepidemiology and Prescription PURPOSE: Disproportionality screening analysis is acknowledged as a tool for performing signal detection in databases of adverse drug reactions (ADRs), e.g., in the European Union (EU) Drug Authority setting. The purpose of this study was to explore the possibility of decreasing false-positive signals of disproportionate reporting (SDR) by calculating the proportional reporting ratio (PRR)-by-therapeutic area (TA), while still maintaining the ability to detect relevant SDRs. METHODS: In the EudraVigilance (EV) Database, output from PRR calculated with a restricted TA comparator background was compared in detail to output from conventional authority-setting PRR calculations for four drugs: bicalutamide, abiraterone, metformin, and vildagliptin, within the TAs of prostate gland disease and type 2 diabetes mellitus. RESULTS: ADR reports per investigated drug ranged from 2,400 to 50,000. The PRR-TA’s ability to detect true-positive SDRs (as acknowledged in approved labeling) was increased compared to the conventional PRR, and performed 8–31 % better than a recently proposed stricter EU-SDR definition. The PRR-TA removed false SDRs confounded by disease or disease spill-over by up to 63 %, while retaining/increasing the number of unclassified SDRs relevant for manual validation, and thereby improving the ratio between confounded SDRs (i.e., noise) and unclassified SDRs for all investigated drugs (possible signals). CONCLUSIONS: The performance of the PRR was improved by background restriction with the PRR-TA method; the number of false-positive SDRs decreased, and the ability to detect true-positive SDRs increased, improving the signal-to-noise ratio. Further development and validation of the method is needed within other TAs and databases, and for disproportionality analysis methods. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00228-014-1658-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-03-07 2014 /pmc/articles/PMC3978377/ /pubmed/24599513 http://dx.doi.org/10.1007/s00228-014-1658-1 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Pharmacoepidemiology and Prescription
Grundmark, Birgitta
Holmberg, Lars
Garmo, Hans
Zethelius, Björn
Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title_full Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title_fullStr Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title_full_unstemmed Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title_short Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
title_sort reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area
topic Pharmacoepidemiology and Prescription
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978377/
https://www.ncbi.nlm.nih.gov/pubmed/24599513
http://dx.doi.org/10.1007/s00228-014-1658-1
work_keys_str_mv AT grundmarkbirgitta reducingthenoiseinsignaldetectionofadversedrugreactionsbystandardizingthebackgroundapilotstudyonanalysesofproportionalreportingratiosbytherapeuticarea
AT holmberglars reducingthenoiseinsignaldetectionofadversedrugreactionsbystandardizingthebackgroundapilotstudyonanalysesofproportionalreportingratiosbytherapeuticarea
AT garmohans reducingthenoiseinsignaldetectionofadversedrugreactionsbystandardizingthebackgroundapilotstudyonanalysesofproportionalreportingratiosbytherapeuticarea
AT zetheliusbjorn reducingthenoiseinsignaldetectionofadversedrugreactionsbystandardizingthebackgroundapilotstudyonanalysesofproportionalreportingratiosbytherapeuticarea